Background: Acute leukemia and hematopoietic stem cell transplantation are risk factors for opportunistic infection and reactivation of many latent infection like cytomegalovirus. Objective: Detection and quantification of cytomegalovirus viremia in patients with acute leukemia after induction chemotherapy and post allogeneic stem cell transplantation patients. Methods: A prospective study enrolled 61 patients with acute leukemia. Forty-eight of them evaluated while induction chemotherapy (group I), while the other 13 within 1-year post bone marrow transplantation (BMT) (group II). In addition, 30 apparently healthy individuals were recruited as (control group), blood samples were collected from all groups. Viral DNA was extracted from 1 ml plasma samples, and then, cytomegalovirus DNA was detected and quantitatively assessed by Taqman quantitative real-time PCR. Results: Twelve (25%) out of 48 patients in group I, 2 (15.4%) out of the 13 patients in group II, and 2 (6.7%) out of 30 in the control group had positive cytomegalovirus viremia. The mean cytomegalovirus viremia was 5.192x102, 2.71x102 and 1.60x102 copies/ml for group I, group II and controls respectively, p=0.056. Conclusion: There is a relatively high prevalence of cytomegalovirus viremia in Iraqi patients with acute leukemia after chemotherapy and post BMT. Real-time PCR assay is helpful for early diagnosis of cytomegalovirus viremia in leukemic patients and used to monitor post BMT patients at risk for cytomegalovirus disease. Keywords: HCMV, acute leukemia, stem cell transplantation, real-time PCR Citation: Al-Toban HA, Al-Marsomy HD, Al-Obaidi AB, Al Tameemi WF, Mohammed MA, Al-Saeed RM, Al-Shemary IK. Molecular detection of cytomegalovirus in a sample of iraqi patients with acute leukemia and stem cell transplantation. Iraqi JMS. 2018; 16(3): 344-352. doi: 10.22578/IJMS.16.3.14
Acute leukemia is the most common hematological malignancies; the malignant cells are immature cells that areincapable of performing their immune system functions. Chemotherapy and Hematopoietic stem cell transplantation (HSCT) are the established treatment for a variety of malignant diseases including acute leukemia. After induction chemotherapy and allogeneic bone marrow transplantation there will be suppression of the immunity and the patients will be susceptible for many opportunistic infections or reactivation of latent infections. Opportunistic infections of T.gondii make an important threat to patients with acute leukemia after the use of intense chemotherapy and immunosuppression drugs following allogeneic HSCT. To detection of T.gondiiin patients with acute leukemia after chemotherapy (induction) courses and post allogeneic Stem cell transplantation patients within the first year and determine copy number of T.gondiiin these groups and compare with apparently healthy individual as control group.A prospective study enrolled 61 patients who diagnosed to have acute leukemia. Forty eight of them had received an induction course of chemotherapy, within one month of diagnosis (group I). While the other 13 acute leukemia patients had assessed after bone marrow transplantation within the first year of diagnosis as group II and 30 apparently healthy individuals as control group. The questionnaire form was given to each patient included: age, sex, residence, Job, Virology screen (HBV,HCV),type of acute leukemia,Chronic disease (DM or HT) if present,frequency of Blood transfusion in addition to CBC. Blood samples were collected from all groups. T. gondii DNA was extracted from 1 ml whole blood samples,and then,T. gondii DNA was detected and measured by Taqman quantitative real-time PCR.The serum to measure IgG and IgM antibody specific to T. gondii wasinvestigated in the control group by an enzyme-linked immune assay (ELISA).T. gondii parasitemia was detected in (8.3%) 4 out of 48 group I patient. While negative in group II and control group. The range of T.gondii load was(6.285×103-17.915×103) copy/ml,the mean of the copy numbers 11458.75± 5120.85.The study is of medical importance as it deals with immunocompromised patients,notably those with cell mediated immunity deficiency who are at risk for life threatening opportunistic infections or reactivation,T.gondii should be looked for Leukemic patients at least by routine serological test for early diagnosis and proper treatment of the patient may reduce the complications of infection and promote better prognosis. And Quantitative PCR is used to monitor PBMT patients at risk for T.gondii disease and for a timely start of preemptive therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.